Brand companies who own GLP-1 products have been pushing the Food and Drug Administration (FDA) to limit their compounding. On August 28, 2024, ...

The American Diabetes Association (ADA) urged healthcare providers against prescribing non-FDA approved compounded GLP-1 and ...

Popular weight loss drugs have been linked to gastrointestinal, mental health, and vision problems, but the benefits appear ...

In the US, liraglutide, semaglutide, and tirzepatide are currently under investigation for their ability to stimulate weight ...

Semaglutide (Wegovy) improved liver fibrosis in patients with metabolic dysfunction-associated steatohepatitis (MASH) and led ...

LANGHORNE, PA — Amplity Health shared valuable findings from its latest study on GLP-1 receptor agonist (GLP-1 RA) usage ...

The ADA recommended doctors avoid prescribing unapproved, off-brand versions of drugs like Wegovy, wading into a dispute that ...

Should employers, patients or insurers cover the $411 billion annual cost for GLP-1 drugs? U.S. healthcare industry grapples with this question as demand grows.

More than 7 million Americans struggling with obesity would become eligible for coverage under the proposed change. (HealthDay News) — The Biden administration is proposing Medicare and Medicaid ...

Currently, Eli Lilly’s GLP-1 drugs Mounjaro and Zepbound (tirzepatide) are not on the FDA’s shortage list but compounded ...

GLP-1 RAs to assist with weight loss have exploded in popularity. Researchers are working to identify which patients will ...

GLP-1s (glucagon-like peptide-1 receptor agonists) are medications used to treat type 2 diabetes and obesity. You’ve probably ...